Corbus Q3 net loss $23.3M ($1.90/sh); cash $104M; CRB-701 ORR 47.6% in HNSCC

Corbus Pharmaceuticals Holdings, Inc.

2025-Q3 EPS reported -$4.73 vs consensus -$1.74 ▼ miss (-171.6%)

Net loss of $23.3M ($1.90 diluted EPS) vs $13.8M ($1.15) in Q3 2024; operating expenses up $8.9M.
Cash, equivalents $104M at Sep 30; raised $73.8M net in Oct-Nov offering extending runway into 2028.
CRB-701 ESMO data: ORR 47.6% (HNSCC), 37.5% (cervical), 55.6% (mUC) at 3.6 mg/kg; registrational study planned mid-2026.
CRB-913 SAD/MAD study on track; Ph1b in obese patients to start Q4 2025.
CRB-601 Phase 1 dose escalation ongoing; first participant dosed Dec 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.